## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($87.98)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251203T170900 | Somewhat-Bearish | Relevance: 100%
- Zimmer Biomet Holdings Inc. (ZBH) shares fell 1.10% to $93.10 on Wednesday, marking its fourth consecutive day of losses. This occurred despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.

**2. Hsbc Holdings PLC Has $34.05 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T094430 | Neutral | Relevance: 100%
- Hsbc Holdings PLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.3% in the second quarter, bringing its total holding to 373,505 shares valued at $34.05 million. Other hedge funds also adjusted their positions in ZBH. The article also provides analyst ratings, stock performance data, and details on recent insider trading activity for Zimmer Biomet.

**3. Korea Investment CORP Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T112154 | Neutral | Relevance: 96%
- Korea Investment CORP significantly increased its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 12.5% in Q2 2025, bringing its total holdings to 111,789 shares valued at approximately $10.20 million. This increase occurred amidst mixed analyst ratings, with an average "Hold" rating and an average price target of $109, despite recent downgrades from some firms and a "Strong Buy" from another. Zimmer Biomet also reported a slight beat on quarterly EPS and provided FY2025 guidance.

**4. Orthobiologics Market | Global Market Analysis Report - 2035**
- Source: Fact.MR | 20251202T034504 | Bullish | Relevance: 84%
- The orthobiologics market is projected to grow from USD 7.1 billion in 2025 to USD 10.9 billion by 2035, at a CAGR of 4.4%. Viscosupplementation will be the leading product type, and spinal fusion will dominate the application segment. The market growth is driven by the increasing prevalence of musculoskeletal disorders, an aging global population, and rising investments in regenerative medicine.

**5. J&J’s US orthopedic leader leaves amid DePuy spinout process**
- Source: MedTech Dive | 20251201T154132 | Neutral | Relevance: 62%
- Leslie Storms, the U.S. president of Johnson & Johnson’s orthopedics business, has left the company to become president of Ethos Veterinary Health. Her departure comes as J&J is in the process of spinning out its orthopedics segment, DePuy Synthes, into a standalone company. This shift means the newly appointed worldwide president, Namal Nawana, will lead the spinout process without Storms' input.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 7)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Canaccord Genui | $93 | $101 | -8% |
| 2025-11-06 | UBS | $88 | $96 | -8% |
| 2025-11-06 | RBC Capital | $101 | $111 | -9% |
| 2025-11-06 | Barclays | $104 | $105 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Canaccord Genui | main | Hold |
| 2025-11-06 | UBS | main | Sell |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-06 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 6.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (7 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.0B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 10.9 |
| Current P/E | 11.4 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.7% to -0.1% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. MACD histogram positive (0.68), confirming momentum. RSI neutral at 46. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.06% (CS: 51) | Neutral |
| RSI_14 | 46.5 | Neutral |
| MACD Histogram | 0.68 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.940x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $93.10
- **Stop Loss:** $87.98 (5.5% risk)
- **Target:** $103.34 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 185
- **Position Value:** $17,223.50
- **Portfolio %:** 17.22%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*